SAN DIEGO – Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), identified for supplying reagents and companies to the life science analysis and biotechnology sectors, has indicated its anticipated complete income for the fiscal 12 months 2024.
Shares fell 5% in after-hours commerce Wednesday.
The corporate’s preliminary year-end outcomes, that are topic to plain year-end changes, counsel that its income is anticipated to align with the mid-point of its beforehand forecasted vary of $255 million to $265 million.
This projection is positioned within the neighborhood of the consensus estimate, which predicts a fiscal 12 months income of roughly $260.78 million.
This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.
(Bloomberg) -- Oil held a decline because the prospect of elevated provide from Iraq weighed…
Simply Eat Takeaway.com has agreed a takeover by a Dutch-based expertise investor which says it…
By Brad Younger, Cash function authorIncreased taxes, smaller pensions, weaker public companies, an older retirement…
Russian oligarchs with hyperlinks to the Kremlin can now be banned from the UK, the…
(Bloomberg) -- Hedge funds are turning much less optimistic on crude oil’s prospects, trimming net-bullish…
(Bloomberg) -- Aluminum prolonged its retreat from an eight-month excessive as sentiment remained cautious following…